Sclerostin alters serum vitamin D metabolite and fibroblast growth factor 23 concentrations and the urinary excretion of calcium

Proceedings of the National Academy of Sciences of the United States of America

Volumn 110, Issue 15, 2013, Pages 6199-6204

  Ryan, Zachary C ^a   Ketha, Hemamalini ^a   McNulty, Melissa S ^a   McGee Lawrence, Meghan ^b   Craig, Theodore A ^a   Grande, Joseph P ^b   Westendorf, Jennifer J ^b,c   Singh, Ravinder J ^b   Kumar, Rajiv ^a,c  

^a Mayo Clinic College of Medicine   (United States)

^b MAYO CLINIC   (United States)

^c MAYO GRADUATE SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA GALACTOSIDASE; CALCIDIOL 1 MONOOXYGENASE; CALCITRIOL; CALCIUM; CYTOCHROME P450; CYTOCHROME P450 27B1; FIBROBLAST GROWTH FACTOR 23; MESSENGER RNA; PARATHYROID HORMONE; PHOSPHORUS; RECOMBINANT PROTEIN; SCLEROSTIN; SECALCIFEROL; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BONE DENSITY; BONE MINERALIZATION; CALCIUM BLOOD LEVEL; CALCIUM EXCRETION; CALCIUM URINE LEVEL; CONTROLLED STUDY; CORTICAL BONE; ENZYME ACTIVITY; GERM LINE; KIDNEY PROXIMAL TUBULE; KNOCKOUT MOUSE; MALE; METABOLITE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; OSSIFICATION; OSTEOBLAST; OSTEOCLAST; PARATHYROID HORMONE BLOOD LEVEL; PHOSPHATE BLOOD LEVEL; PRIORITY JOURNAL; TRABECULAR BONE; URINARY EXCRETION; VITAMIN D METABOLISM; WILD TYPE;

25-HYDROXYVITAMIN D3 1-ALPHA-HYDROXYLASE; ANIMALS; BETA-GALACTOSIDASE; BONE DENSITY; CALCIUM; CHROMATOGRAPHY, LIQUID; FEMALE; FIBROBLAST GROWTH FACTORS; GLYCOPROTEINS; HETEROZYGOTE; MALE; MASS SPECTROMETRY; MICE; MICE, KNOCKOUT; MUTATION; OSTEOBLASTS; OSTEOCLASTS; OSTEOCYTES; VITAMIN D; X-RAY MICROTOMOGRAPHY;

MUS;

EID: 84876053276     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1221255110     Document Type: Article

References (52)

1. ten Dijke P, Krause C, de Gorter DJ, Löwik CW, van Bezooijen RL (2008) Osteocytederived sclerostin inhibits bone formation: its role in bone morphogenetic protein and Wnt signaling. J Bone Joint Surg Am 90(Suppl 1):31-35.
2. Winkler DG, et al. (2003) Osteocyte control of bone formation via sclerostin, a novel BMP antagonist. EMBO J 22(23):6267-6276.
3. Winkler DG, et al. (2005) Sclerostin inhibition of Wnt-3a-induced C3H10T1/2 cell differentiation is indirect and mediated by bone morphogenetic proteins. J Biol Chem 280(4):2498-2502.
4. Sutherland MK, et al. (2004) Sclerostin promotes the apoptosis of human osteoblastic cells: A novel regulation of bone formation. Bone 35(4):828-835.
5. Veverka V, et al. (2009) Characterization of the structural features and interactions of sclerostin: Molecular insight into a key regulator of Wnt-mediated bone formation. J Biol Chem 284(16):10890-10900.
6. Balemans W, et al. (2001) Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST). Hum Mol Genet 10(5):537-543.
7. Semenov MV, He X (2006) LRP5 mutations linked to high bone mass diseases cause reduced LRP5 binding and inhibition by SOST. J Biol Chem 281(50):38276-38284.
8. Ellies DL, et al. (2006) Bone density ligand, Sclerostin, directly interacts with LRP5 but not LRP5G171V to modulate Wnt activity. J Bone Miner Res 21(11):1738-1749.
9. Li X, et al. (2005) Sclerostin binds to LRP5/6 and antagonizes canonical Wnt signaling. J Biol Chem 280(20):19883-19887.
10. Craig TA, Bhattacharya R, Mukhopadhyay D, Kumar R (2010) Sclerostin binds and regulates the activity of cysteine-rich protein 61. Biochem Biophys Res Commun 392(1):36-40.
11. Craig TA, Kumar R (2010) Sclerostin-erbB-3 interactions: Modulation of erbB-3 activity by sclerostin. Biochem Biophys Res Commun 402(2):421-424.
12. Devarajan-Ketha H, Craig TA, Madden BJ, Robert Bergen H, 3rd, Kumar R (2012) The sclerostin-bone protein interactome. Biochem Biophys Res Commun 417(2):830-835.
13. Loots GG, et al. (2005) Genomic deletion of a long-range bone enhancer misregulates sclerostin in Van Buchem disease. Genome Res 15(7):928-935.
14. Brunkow ME, et al. (2001) Bone dysplasia sclerosteosis results from loss of the SOST gene product, a novel cystine knot-containing protein. Am J Hum Genet 68(3):577-589.
15. Li X, et al. (2008) Targeted deletion of the sclerostin gene in mice results in increased bone formation and bone strength. J Bone Miner Res 23(6):860-869.
16. Collette NM, et al. (2012) Targeted deletion of Sost distal enhancer increases bone formation and bone mass. Proc Natl Acad Sci USA 109(35):14092-14097.
17. Lin C, et al. (2009) Sclerostin mediates bone response to mechanical unloading through antagonizing Wnt/beta-catenin signaling. J Bone Miner Res 24(10):1651-1661.
18. Johnson JA, Kumar R (1994) Vitamin D and renal calcium transport. CurrOpin Nephrol Hypertens 3(4):424-429.
19. Borke JL, Penniston JT, Kumar R (1990) Recent advances in calcium transport by the kidney. Semin Nephrol 10(1):15-23.
20. Tanaka Y, Deluca HF (1974) Role of 1, 25-dihydroxyvitamin D3 in maintaining serum phosphorus and curing rickets. Proc Natl Acad Sci USA 71(4):1040-1044.
21. Georgaki H, Puschett JB (1982) Acute effects of a " physiological" dose of 1, 25-dihydroxy vitamin D3 on renal phosphate transport. Endocr Res Commun 9(2):135-143.
22. Puschett JB, et al. (1972) The acute renal tubular effects of 1, 25-dihydroxycholecalciferol. Proc Soc Exp Biol Med 141(1):379-384.
23. Berndt T, Kumar R (2009) Novel mechanisms in the regulation of phosphorus homeostasis. Physiology (Bethesda) 24:17-25.
24. DeLuca HF, Schnoes HK (1983) Vitamin D: Recent advances. Annu Rev Biochem 52:411-439.
25. Wasserman RH, et al. (1992) Intestinal calcium transport and calcium extrusion processes at the basolateral membrane. J Nutr 122(3, Suppl): (Suppl):662-671.
26. DeLuca HF, Schnoes HK (1976) Metabolism and mechanism of action of vitamin D. Annu Rev Biochem 45:631-666.
27. Garabedian M, Holick MF, Deluca HF, Boyle IT (1972) Control of 25-hydroxycholecalciferol metabolism by parathyroid glands. Proc Natl Acad Sci USA 69(7):1673-1676.
28. Omdahl JL, Gray RW, Boyle IT, Knutson J, DeLuca HF (1972) Regulation of metabolism of 25-hydroxycholecalciferol by kidney tissue in vitro by dietary calcium. Nat New Biol 237(71):63-64.
29. Tanaka Y, Deluca HF (1973) The control of 25-hydroxyvitamin D metabolism by inorganic phosphorus. Arch Biochem Biophys 154(2):566-574.
30. Schiavi SC, Kumar R (2004) The phosphatonin pathway: New insights in phosphate homeostasis. Kidney Int 65(1):1-14.
31. Shimada T, et al. (2004) Targeted ablation of Fgf23 demonstrates an essential physiological role of FGF23 in phosphate and vitaminD metabolism. J Clin Invest 113(4):561-568.
32. van Bezooijen RL, et al. (2004) Sclerostin is an osteocyte-expressed negative regulator of bone formation, but not a classical BMP antagonist. J Exp Med 199(6):805-814.
33. Pereira RC, et al. (2009) Patterns of FGF-23, DMP1, and MEPE expression in patients with chronic kidney disease. Bone 45(6):1161-1168.
34. Wesseling-Perry K (2010) FGF-23 in bone biology. Pediatr Nephrol 25(4):603-608.
35. Yuan B, et al. (2008) Aberrant Phex function in osteoblasts and osteocytes alone underlies murine X-linked hypophosphatemia. J Clin Invest 118(2):722-734.
36. Bowe AE, et al. (2001) FGF-23 inhibits renal tubular phosphate transport and is a PHEX substrate. Biochem Biophys Res Commun 284(4):977-981.
37. Boyle IT, Gray RW, DeLuca HF (1971) Regulation by calcium of in vivo synthesis of 1, 25-dihydroxycholecalciferol and 21, 25-dihydroxycholecalciferol. Proc Natl Acad Sci USA 68(9):2131-2134.
38. Costanzo LS, Windhager EE (1980) Effects of PTH, ADH, and cyclic AMP on distal tubular Ca and Na reabsorption. Am J Physiol 239(5):F478-F485.
39. Costanzo LS, Windhager EE (1980) Effects of parathyroid hormone and cyclic AMP on distal tubular calcium and sodium transport. Contrib Nephrol 20:114-117.
40. Valenzuela DM, et al. (2003) High-throughput engineering of the mouse genome coupled with high-resolution expression analysis. Nat Biotechnol 21(6):652-659.
41. Takahashi H, Liu C (2010) Archiving and distributing mouse lines by sperm cryopreservation, IVF, and embryo transfer. Methods Enzymol 476:53-69.
42. Mödder UI, et al. (2004) Effects of loss of steroid receptor coactivator-1 on the skeletal response to estrogen in mice. Endocrinology 145(2):913-921.
43. Connerty HV, Briggs AR (1966) Determination of serum calcium by means of orthocresolphthalein complexone. Am J Clin Pathol 45(3):290-296.
44. Muñoz MA, Balón M, Fernandez C (1983) Direct determination of inorganic phosphorus in serum with a single reagent. Clin Chem 29(2):372-374.
45. Horio M, Orita Y (1996) Comparison of Jaffé rate assay and enzymatic method for the measurement of creatinine clearance. Nippon Jinzo Gakkai Shi 38(7):296-299.
46. Nesbitt T, Byun JK, Drezner MK (1996) Normal phosphate transport in cells from the S2 and S3 segments of Hyp-mouse proximal renal tubules. Endocrinology 137(3):943-948.
47. Nesbitt T, et al. (1995) Phosphate transport in immortalized cell cultures from the renal proximal tubule of normal and Hyp mice: evidence that the HYP gene locus product is an extrarenal factor. J Bone Miner Res 10(9):1327-1333.
48. Bensamoun SF, et al. (2006) TGFbeta inducible early gene-1 knockout mice display defects in bone strength and microarchitecture. Bone 39(6):1244-1251.
49. Bouxsein ML, et al. (2010) Guidelines for assessment of bone microstructure in rodents using micro-computed tomography. J Bone Miner Res 25(7):1468-1486.
50. Bouxsein ML, et al. (2004) Mapping quantitative trait loci for vertebral trabecular bone volume fraction and microarchitecture in mice. J Bone Miner Res 19(4):587-599.
51. Pereira FA (2001) Whole-mount histochemical detection of beta-galactosidase activity. Curr Protoc Mol Biol Chapter 14: Unit14.14.
52. McGee-Lawrence ME, et al. (2013) Histone deacetylase 3 is required for maintenance of bone mass during aging. Bone 52(1):296-307.